

Inmaculada LÃ³pez Montesinos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3676632/publications.pdf>

Version: 2024-02-01

8
papers

68
citations

1937685

4
h-index

1720034

7
g-index

8
all docs

8
docs citations

8
times ranked

78
citing authors

#	ARTICLE	IF	CITATIONS
1	Aminoglycoside or Polymyxin Monotherapy for Treating Complicated Urinary Tract Infections Caused by Extensively Drug-Resistant <i>Pseudomonas aeruginosa</i> : A Propensity Score-Adjusted and Matched Cohort Study. <i>Infectious Diseases and Therapy</i> , 2022, 11, 335-350.	4.0	8
2	Comparison of Hospitalized Coronavirus Disease 2019 and Influenza Patients Requiring Supplemental Oxygen in a Cohort Study: Clinical Impact and Resource Consumption. <i>Clinical Infectious Diseases</i> , 2022, 75, 2225-2238.	5.8	2
3	Impact of a Nosocomial COVID-19 Outbreak on a Non-COVID-19 Nephrology Ward during the First Wave of the Pandemic in Spain. <i>Antibiotics</i> , 2021, 10, 619.	3.7	4
4	Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant <i>Pseudomonas aeruginosa</i> and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates. <i>Microbiology Spectrum</i> , 2021, 9, e0058521.	3.0	18
5	A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?. <i>Infectious Diseases and Therapy</i> , 2021, 10, 2677-2699.	4.0	4
6	Comparative Analysis of Dalbavancin versus Other Antimicrobial Options for Gram-Positive Cocci Infections: Effectiveness, Hospital Stay and Mortality. <i>Antibiotics</i> , 2021, 10, 1296.	3.7	4
7	Risk Factors for Mortality among Patients with <i>Pseudomonas aeruginosa</i> Bloodstream Infections: What Is the Influence of XDR Phenotype on Outcomes?. <i>Journal of Clinical Medicine</i> , 2020, 9, 514.	2.4	27
8	Comparison of Ceftolozane/Tazobactam Infusion Regimens in a Hollow-Fiber Infection Model against Extensively Drug-Resistant <i>Pseudomonas aeruginosa</i> Isolates. <i>Microbiology Spectrum</i> , 0, , .	3.0	1